Immunovant (IMVT) Net Cash Flow (2019 - 2026)

Immunovant has reported Net Cash Flow for 8 years, with the latest figure at -$91.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 126.91% year-over-year to -$91.4 million; the trailing twelve-month figure through Mar 2026 stood at $188.4 million (up 142.02% YoY), and the FY2026 full-year result was $188.4 million, up 142.02% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$91.4 million, down from $472.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $472.3 million in Q4 2025, with the low at -$114.5 million in Q2 2025.
• Historically, Net Cash Flow has averaged $22.0 million across 5 years, with a median of -$58.3 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 211.43% — and 2023, when it soared 1650.83%.
• Immunovant's Net Cash Flow stood at $24.1 million in 2022, then soared by 1650.83% to $422.6 million in 2023, then plunged by 123.21% to -$98.1 million in 2024, then jumped by 581.39% to $472.3 million in 2025, then slumped by 119.36% to -$91.4 million in 2026.
• The last three Net Cash Flow figures came in at -$91.4 million (Q1 2026), $472.3 million (Q4 2025), and -$77.9 million (Q3 2025), per Business Quant data.